119th Congress · introduced in the House · Mar 16, 2026
Nitrous Oxide Safety Act of 2026
Official title from Congress.gov
Latest action (Sep 16, 2026): Ordered to be Reported by the Yeas and Nays: 36 - 0.
View on Congress.govPolicy area: Commerce
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Ordered to be Reported by the Yeas and Nays: 36 - 0.
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Commerce, Manufacturing, and Trade.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Consumer affairs · Drug safety, medical device, and laboratory regulation · Food supply, safety, and labeling · Hazardous wastes and toxic substances · Product safety and quality · Research and development
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
2 citations.
AIR LIQUIDE USA LLC · lobbying firm or registrant: AIR LIQUIDE USA LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Alcohol and Drug Abuse
$250,000
Spent on own lobbying
Ensuring the safe use of nitrous oxide for industrial purposes and to avoid its misuse as a recreational drug. Including H.R.7945 and S.4997.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CALIFORNIA MEDICAL ASSOCIATION INC · lobbying firm or registrant: CALIFORNIA MEDICAL ASSOCIATION INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$40,000
Spent on own lobbying
H.R. 3164: Ensuring Community Access to Pharmacist Services Act; all provisions H.R. 4710: No Surprises Act Enforcement Act; all provisions H.R. 7945: Nitrous Oxide Safety Act of 2026; all provisions S. 2420: No Surprise Act Enforcement Act; all provisions
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing